Sir,
Olsen et al (2003) claim in their article that organised mammography screening can operate without overdiagnosis of breast cancer.
This paper contains no statistical analysis and does not report the number of detected cancers, so the readers can do the proper statistical analysis themselves. In particular, it does not report the incidence increase in per cent, and the readers are left to look at some figures.
When I look at Figure 2, I read that the cumulative risk in Copenhagen increases from about 5.25% (1989–91) to 6.25% (1993–95). This gives 19% increase. Comparing the 5.75% cumulative risk on Fyn in 1992–93 to 6.75% cumulative risk in 1996–97 shows a 17% increase.
There was some opportunistic screening before organised screening started in Denmark (Olsen et al, 2003), so there is reason to attribute some of the incidence increase before 1993 to mammography. If cumulative risk in the second screening round is compared to the cumulative risk in 1987–89 (Copenhagen) or 1988–89 (Fyn), I get at least 30 and 50% incidence increases, respectively.
The authors should also have studied incidence in the age group 70–74 years after some years with screening in the age group 50–69 years (Spix et al, 2003). If mammography screening brings the time of diagnosis forward, incidence in the age group 70–74 years should decline. The difference between incidence increase in the age group 50–69 years and decline in the age group 70–74 years is the correct definition of overdiagnosis (Spix et al, 2003).
The authors do not report ductal carcinoma in situ (DCIS). On including DCIS (as Olsen and Gøtzsche (2001) did), one would assume that overdiagnosis today must be a much larger problem than reported by Olsen and Gøtzsche in the screening trials 20 years ago. In contrast, Etzioni et al (2002) recently reported only 30% overdiagnosis when screening with prostate-specific antigen for prostate cancer.
I think that this paper actually shows that overdiagnosis is a serious problem when screening with mammography.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94: 981–990
Olsen O, Gøtzsche PC (2001) Cochrane review on screening for breast cancer with mammography. Lancet 358: 1340–1342
Olsen AH, Jensen A, Njor SH, Villadsen E, Schwartz W, Vejborg I, Lynge E (2003) Breast cancer incidence after the start of mammography screening in Denmark. Br J Cancer 83: 362–365
Spix C, Michaelis J, Berthold F, Erttmann R, Sander J, Schilling FH (2003) Lead-time and overdiagnosis in estimation in neuroblastoma screening. Stat Med 22: 2877–2892
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Zahl, PH. Overdiagnosis of breast cancer in Denmark. Br J Cancer 90, 1686 (2004). https://doi.org/10.1038/sj.bjc.6601738
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6601738
This article is cited by
-
Most Breast Cancer Screening Trials Have a Flawed Design
Indian Journal of Surgery (2011)